Smokers having Activating EGFR Mutant Non-Small CellLung Cancer Might Benefit from EGFR-TKI Treatment –Single-Center Experience

TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY, cilt.35, sa.3, ss.334-339, 2020 (ESCI)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 35 Sayı: 3
Basım Tarihi: 2020
Doi Numarası: 10.5505/tjo.2020.2207
Dergi Adı: TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.334-339
Anahtar Kelimeler: Epidermal growth factor receptor, smoking, tyrosine kinase inhibitors, GROWTH-FACTOR-RECEPTOR, OPEN-LABEL, NEVER SMOKERS, 1ST-LINE TREATMENT, CIGARETTE-SMOKING, GENE-MUTATIONS, PHASE-III, GEFITINIB, CHEMOTHERAPY, RESISTANCE
Marmara Üniversitesi Adresli: Evet

OBJECTIVE